Archive: 10/12/2017
Sequencing offers clues to progression toward multiple myeloma
Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms. The ...
Dec 10, 2017
Global CAR T therapy trial shows high rates of durable remission for NHL
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) ...
Dec 10, 2017
Phase 2 CAR-T study reports significant remission rates at 15-month follow up
A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment ...
Dec 10, 2017
Major recall of Lactalis baby milk over salmonella fears (Update)
French baby-milk maker Lactalis and health authorities have ordered a major international product recall because of fears of salmonella contamination, following 26 cases of children falling sick in France.
Dec 10, 2017
Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...
Dec 10, 2017
Rapid responses, few adverse effects in targeted agent in Phase1 trial in rare blood disorder
In a Phase 1 trial, patients with an advanced or aggressive form of systemic mastocytosis (AdvSM), a rare blood disorder, had rapid and durable responses with few adverse effects following treatment with an investigational ...
Dec 10, 2017